PE20100057A1 - Sistema de suministro intrauterino para la liberacion controlada de progestageno - Google Patents

Sistema de suministro intrauterino para la liberacion controlada de progestageno

Info

Publication number
PE20100057A1
PE20100057A1 PE2009000913A PE2009000913A PE20100057A1 PE 20100057 A1 PE20100057 A1 PE 20100057A1 PE 2009000913 A PE2009000913 A PE 2009000913A PE 2009000913 A PE2009000913 A PE 2009000913A PE 20100057 A1 PE20100057 A1 PE 20100057A1
Authority
PE
Peru
Prior art keywords
progestagen
bleeding
controlled release
delivery system
drug
Prior art date
Application number
PE2009000913A
Other languages
English (en)
Inventor
Bernd Duesterberg
Manja Ahola
Jyrki Pihlaja
Heikki Lyytikainen
Harri Jukarainen
Satu Kleemola
Tero Parkatti
Original Assignee
Bayer Schering Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40020198&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Oy filed Critical Bayer Schering Pharma Oy
Publication of PE20100057A1 publication Critical patent/PE20100057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Communication Control (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

REFERIDA A UN SISTEMA DE SUMINISTRO INTRAUTERINO PARA LA LIBERACION CONTROLADA DE PROGESTAGENO O DE UNA DROGA CON ACTIVIDAD PROGESTAGENA, DONDE DICHO SISTEMA COMPRENDE UNA ESTRUCTURA DE UN CUERPO CON AL MENOS UN DEPOSITO QUE COMPRENDE UN NUCLEO, OPCIONALMENTE, CUBIERTO DE UNA MEMBRANA. DENTRO DEL PROGESTAGENO O DROGA CON ACTIVIDAD PROGESTAGENICA SE ENCUENTRAN EL ACETATO DE CITROPERONA, LEVONORGESTREL, DROSPIRENONA, NORGESTIMATO, ETONOGESTREL, NORETISTERONA, ENTRE OTROS; EL NUCLEO Y LA MEMBRANA QUE LO CUBRE CONSISTEN EN UNA COMPOSICION POLIMERICA QUE COMPRENDE: POLI(DIMETILSILOXANO), UN POLIMERO BASADO EN SILOXANO QUE COMPRENDE GRUPOS 3,3,3-TRIFLUOROPROPILO UNIDOS A LOS ATOMOS DE Si DE LAS UNIDADES DE SILOXANO, GRUPOS POLI(OXIDO DE ALQUILENO) TAL COMO POLI(OXIDO DE ETILENO). DICHO SISTEMA PUEDE COMPRENDER, ADICIONALMENTE, UNA SUSTANCIA CON CAPACIDAD DE EVITAR O SUPRIMIR EL SANGRADO ENDOMETRIAL TAL COMO EL ACIDO TRANEXAMICO, ACIDO MEFENAMICO, DANAZOL, ENTRE OTROS, Y ES UTIL PARA LA ANTICONCEPCION, PARA EVITAR O SUPRIMIR EL SANGRADO ENDOMETRIAL ANORMAL Y/O IRREGULAR Y PARA LOGRAR UNA RAPIDA INDUCCION DE LA AMENORREA
PE2009000913A 2008-07-03 2009-07-01 Sistema de suministro intrauterino para la liberacion controlada de progestageno PE20100057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397516A EP2140860A1 (en) 2008-07-03 2008-07-03 An improved method of contraception

Publications (1)

Publication Number Publication Date
PE20100057A1 true PE20100057A1 (es) 2010-02-25

Family

ID=40020198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000913A PE20100057A1 (es) 2008-07-03 2009-07-01 Sistema de suministro intrauterino para la liberacion controlada de progestageno

Country Status (22)

Country Link
US (3) US20110146693A1 (es)
EP (3) EP2140860A1 (es)
JP (3) JP2011526609A (es)
KR (2) KR20110026516A (es)
CN (2) CN103976816A (es)
AR (1) AR072544A1 (es)
CA (1) CA2730040A1 (es)
CL (1) CL2009001490A1 (es)
CY (1) CY1120878T1 (es)
DK (1) DK2905014T3 (es)
ES (1) ES2673154T3 (es)
HR (1) HRP20180869T1 (es)
HU (1) HUE037520T2 (es)
LT (1) LT2905014T (es)
PE (1) PE20100057A1 (es)
PL (1) PL2905014T3 (es)
PT (1) PT2905014T (es)
SI (1) SI2905014T1 (es)
TR (1) TR201807996T4 (es)
TW (2) TWI602556B (es)
UY (1) UY31957A (es)
WO (1) WO2010000943A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2349143T4 (en) 2008-09-17 2016-11-28 Bayer Oy introducer
FI20080524A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
WO2012121811A1 (en) * 2011-03-04 2012-09-13 Arstat, Inc. Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
SE539540C2 (sv) * 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
EP3057573A1 (en) * 2013-10-18 2016-08-24 Bayer Oy Intrauterine delivery system
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2015189853A1 (en) 2014-06-13 2015-12-17 Meril Endo Surgery Private Limited An intrauterine device
TWI730948B (zh) * 2014-12-08 2021-06-21 芬蘭商拜耳股份有限公司 新穎的熱塑性聚胺甲酸酯，彼等材料於製造子宮內系統之ｔ-框架之用途及由此等材料製成之ｔ-框架
EP3247327B1 (en) * 2015-01-21 2019-08-07 Bayer Oy Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing
WO2016171543A1 (en) 2015-04-22 2016-10-27 Cadens Beheer B.V. Improved contraceptive methods and compositions and devices for use therein
JP6898856B2 (ja) 2015-05-13 2021-07-07 バイエル・オーイュー 長時間作用型薬物送達装置および避妊におけるその使用
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6936801B2 (ja) * 2015-12-21 2021-09-22 バイエル・オーイュー 薬剤送達装置の製造方法およびその方法に従って製造された薬剤送達装置
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
GB2555373A (en) * 2016-08-23 2018-05-02 Reproductive Medicine And Gynaecology Associates Ltd Implant
AU201617347S (en) * 2016-12-23 2017-01-23 Jurox Pty Ltd intravaginal device
US11666552B2 (en) * 2017-09-27 2023-06-06 Bayer Oy Method for modifying release of a therapeutically active agent from an elastomeric matrix
US20200268932A1 (en) * 2019-02-22 2020-08-27 Arsenal Aaa, Llc. Crosslinkable polymer compositions
KR102260999B1 (ko) * 2019-03-27 2021-06-04 (주)엠케어코리아 난소암 검사용 임플란트 및 이를 포함하는 검사킷 및 이를 이용한 난소암 검사방법
CN110215447A (zh) * 2019-06-14 2019-09-10 上海市计划生育科学研究所 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物
US11571329B2 (en) 2019-11-21 2023-02-07 Coopersurgical, Inc. Packaging systems for implantable devices and related methods
CN116807727B (zh) * 2023-08-29 2023-11-21 上海宇度医学科技股份有限公司 一种妇产科医师用临床取环器

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US4188951A (en) 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4495934A (en) 1978-07-25 1985-01-29 Shaw Jr Seth T IUD Arrangement
US4284074A (en) * 1978-07-26 1981-08-18 Shaw Jr Seth T IUD Arrangement
AU538963B2 (en) 1979-07-09 1984-09-06 Seth Thomas Shaw Jr. Drug for use with an iud
FR2539027B1 (fr) * 1983-01-07 1987-03-06 Levrier Marc Systeme endo-uterin contraceptif et therapeutique associant cuivre, argent, hormone naturelle et acide iso amino caproique
NL8603216A (nl) * 1986-12-17 1988-07-18 Kurz Karl Heinz Inrichting om in de uterus te plaatsen.
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
FI94947C (fi) 1994-04-05 1995-11-27 Maillefer Nokia Holding Sovitelma lankamaisia tuotteita puolaavan koneen yhteydessä
FI97944C (fi) 1994-07-05 1997-03-25 Leiras Oy Vaikuttavaa ainetta luovuttava laite
FI97947C (fi) 1994-09-27 1997-03-25 Leiras Oy Menetelmä lääkepreparaatin valmistamiseksi
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
EP0944382A1 (en) * 1996-09-30 1999-09-29 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
FI103051B1 (fi) 1997-08-22 1999-04-15 Leiras Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US20050033163A1 (en) 2001-04-24 2005-02-10 Impres Medical, Inc. Intrauterine implant and methods of use
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
WO2002038159A1 (fr) * 2000-11-10 2002-05-16 Mitsubishi Pharma Corporation Medicaments pour l'hyperplasie endometriale
WO2003017971A1 (en) * 2001-08-31 2003-03-06 Schering Oy Drug delivery system
JP2003221338A (ja) * 2002-01-29 2003-08-05 Masao Igarashi 子宮腺筋症治療製剤
EP1620060B1 (en) * 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
FI123188B (fi) * 2005-04-05 2012-12-14 Bayer Oy Ultraäänellä havaittavissa oleva kohdunsisäinen järjestelmä
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
CN100441156C (zh) * 2006-09-30 2008-12-10 华中科技大学 一种复合材料宫内节育器

Also Published As

Publication number Publication date
PT2905014T (pt) 2018-06-22
US20180263899A1 (en) 2018-09-20
HUE037520T2 (hu) 2018-09-28
JP2014129412A (ja) 2014-07-10
EP2140860A1 (en) 2010-01-06
PL2905014T3 (pl) 2018-10-31
CN103976816A (zh) 2014-08-13
TW201002288A (en) 2010-01-16
DK2905014T3 (en) 2018-06-25
EP2313084A1 (en) 2011-04-27
US20110146693A1 (en) 2011-06-23
US20140127280A1 (en) 2014-05-08
TW201601699A (zh) 2016-01-16
UY31957A (es) 2010-01-29
CY1120878T1 (el) 2019-12-11
TWI602556B (zh) 2017-10-21
US9999592B2 (en) 2018-06-19
TR201807996T4 (tr) 2018-06-21
JP6008893B2 (ja) 2016-10-19
KR101659530B1 (ko) 2016-09-23
KR20150136143A (ko) 2015-12-04
ES2673154T3 (es) 2018-06-20
EP2905014A1 (en) 2015-08-12
AR072544A1 (es) 2010-09-08
JP2011526609A (ja) 2011-10-13
CN102088954A (zh) 2011-06-08
KR20110026516A (ko) 2011-03-15
HRP20180869T1 (hr) 2018-08-24
SI2905014T1 (en) 2018-08-31
CA2730040A1 (en) 2010-01-07
EP2905014B1 (en) 2018-04-25
CL2009001490A1 (es) 2010-08-06
US10532025B2 (en) 2020-01-14
WO2010000943A1 (en) 2010-01-07
LT2905014T (lt) 2018-07-10
JP2016166245A (ja) 2016-09-15
EP2313084A4 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
PE20100057A1 (es) Sistema de suministro intrauterino para la liberacion controlada de progestageno
DOP2010000154A (es) Sistema de administracion vaginal
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
CO7160098A2 (es) Suministro de fármaco biodegradable para las composiciones hidrofóbicas
PE20080765A1 (es) Formas de dosificacion farmaceutica
CO6210806A2 (es) Composiciones con forma de dosificacion simple para liberar multiples farmacos a diferentes velocidades de liberacion
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
TR201906738T4 (tr) Bir çekirdek ve bir kılıf içeren kontrasepsiyonda kullanıma yönelik ilaç taşıyıcı sistem.
DOP2010000253A (es) Sistema de administracion de drogas con efecto estabilizante
WO2010144698A3 (en) Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
CL2011003065A1 (es) Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis.
CO7071123A2 (es) Formulaciones basadas en dispersiones solidas
WO2018081726A3 (en) Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
AR076588A1 (es) Sistema de liberacion vaginal
CL2015001574A1 (es) Terapia combinada para el cancer
MX2018004445A (es) Particulas coloidales para su uso en medicina.
CO6480929A2 (es) Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer
AR106543A1 (es) Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
US20220370505A1 (en) Prevention and treatment of kidney failure by administration of fibroblasts and products thereof
BR112015000647A2 (pt) composições orais líquidas e pediátricas que contêm nepadutant

Legal Events

Date Code Title Description
FG Grant, registration